The microbiota-gut-brain axis
The gastrointestinal (GI) tract has been described to be home to more than 100 trillion microscopic bacteria and to host to more than 70% of all bodily flora (Vyas and Ranganathan, 2012) . The collection of microorganisms colonizing the GI tract is termed 'gut microbiota' (Bäckhed et al., 2005; Neish, 2009) , and it mainly comprises bacteria (Guarner, 2005; Balzola et al., 2010) . Frequently, the importance of gut microbiota has been related to the extended belief that bacteria residing in the human body outnumber human cells by a factor of 10 or more (10 : 1 ratio); however, a recent research has updated this ratio to closer to 1 : 1. Nonetheless, such a modification in numbers should not change the importance of host-microbiota interactions (Sender et al., 2016) .
The gut is colonized by bacteria from birth and rapidly reaches concentrations up to 10 12 organisms per gram of luminal contents in the colon (Ohland and Jobin, 2015) . The composition of microbiota in the infant depends on different factors, such as the type of delivery (vaginal or cesarean), diet (breast milk or formula), or exposure to antibiotics. The gut microbiome contributes to the early programming of epithelial barrier function, angiogenesis, and innate and host immune function (Rodríguez-Fandiño et al., 2010) , and evidence from experimental and clinical studies supports the fact that alterations in the pattern of GI colonization have long-term consequences on immune function. After weaning, microbiome composition changes, and by 2 years of age, it is similar to that of adults (Salazar et al., 2014) . The adult microbiome includes ∼ 30 species of Bifidobacterium, 52 species of Lactobacillus, and others, such as Streptococcus and Enterococcus (Wallace et al., 2011) . In each region of the gut, different microorganisms are found. Thus, Gram-positive facultative anaerobic bacteria predominate in the proximal small intestine and Gramnegative anaerobes in its distal part, whereas in the colon, obligate anaerobes outnumber facultative anaerobes. The gut microbiota produces many metabolic substances, which depend on each individual's microbiome and are critically affected by the individual's diet (Blaut and Clavel, 2007) ; microbiome-released metabolites may include several vitamins (folate and biotin), short chain fatty acids (SCFAs) (propionate, butyrate, and acetate), and neuroactive metabolites (serotonin and γ-butyric acid), among others (Sharon et al., 2014) .
The gut microbiota has been described to exert a profound influence on brain physiology and behavior (Cryan and Dinan, 2012; Borre et al., 2014; Dinan et al., 2014; Carabotti et al., 2015) through a variety of mechanisms (Chichlowski and Rudolph, 2015) . Locally, bacterial products promote myoelectric activity, activate the enteric nervous system (ENS), and stimulate primary afferent nerves (Husebye et al., 1994; Al-Nedawi et al., 2015) . Furthermore, circulating bacterial metabolites seem to elicit changes in behavior (Chichlowski and Rudolph, 2015) , but at the same time, the microbiome During recent decades, interest in the relationship between gut microbiota and disease states has grown considerably. Microbiota has become the focal point of research in relation to several pathological conditions including digestive diseases and emotional and painrelated disorders (Mayer et al., 2015) . Indeed, several strategies have been developed to change, both qualitative and/or quantitatively, the microbiome, mainly, the reduction of gut microbiota by the administration of antibiotics, and its enhancement by the administration of probiotics, or even by fecal transplants (Fond et al., 2015; Martin and Kochhar, 2015) . Indeed, specific animal models have been developed in this regard. A new model in which human fecal microbiota is introduced to germfree (GF) mice through microbiota transplantation has been recently proposed. However, there are some limitations that need to be elucidated, including whether fecal transplantation is successfully performed, and whether human dysbiosis patterns are reproduced in the animal model (Arrieta et al., 2016) . Here, among the several strategies available, we will focus on the use of probiotics, in both human and animal models, to modify gut microbiota.
Probiotics
Probiotics are defined by the Food and Agriculture Organization and the International Scientific Association for Probiotics and Prebiotics as 'live microorganisms that, when administered in adequate amounts, confer a health benefit on the host' (Hill et al., 2014) . Historically, the concept of probiotics began around 1900 when the Nobel laureate Elie Metchnikoff discovered that consumption of live bacteria (Lactobacillus bulgaricus) in yogurt or fermented milk improved the biological features of the GI tract (Mackowiak, 2013) .
The most commonly used probiotics are lactic acid bacteria, from the genera Lactobacillus and Bifidobacterium, but also include yeasts such as Saccharomyces boulardii. These species are nonpathogenic and can resist the harsh luminal environment of the GI tract (Bezkorovainy, 2001 ). Probiotic consumption is reported to exert a myriad of positive effects including enhancing immune response, balancing the colonic microbiota, vaccine adjuvant effects, reduction of fecal enzymes implicated in cancer initiation, treatment of diarrhea associated with travelling, antibiotic therapy, control of rotavirus and Clostridium difficile-induced colitis, and prevention of ulcers related to Helicobacter pylori (Kaur et al., 2002; Khoder et al., 2016) . Moreover, some probiotics have even been described as protective against heavy metal exposure (Ojekunle et al., 2017) . Beneficial effects of probiotics are mediated by different mechanisms including competition against pathogenic bacteria in their binding to the intestinal epithelial cells, enhancement of intestinal epithelial barrier function, inhibition of the growth of pathogens by secreting antimicrobial peptides, and/or enhancement of serum IgA production, among others (reviewed in Upadhyay and Moudgal, 2012; Hardy et al., 2013) .
To guarantee the survival of probiotics, microencapsulated or coated probiotic strains are sometimes required (Kailasapathy, 2002; Haghshenas et al., 2015; Nami et al., 2017) . Remarkably, a newer generation of probiotics is based on their capacity to form biofilms, and on the advances of these probiotic encapsulation techniques (Salas-Jara et al., 2016) . Occasionally, nonliving probiotic strains, known as 'para-probiotics' or 'ghost probiotics', have also been employed (Adams, 2010; Taverniti and Guglielmetti, 2011) . Actually, these nonviable probiotics, resulting from exposure to high temperatures or irradiation, or some probiotic fractions, such as DNA, have been shown to induce immune system stimulation against vancomycinresistant enterococci (Sakai et al., 2006) and have been reported to enhance tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 production (Marin et al., 1997) , to protect immune-deficient mice against Candida albicans (Wagner et al., 2000) , to improve the anti-inflammatory response in rats with experimentally induced colitis (Rachmilewitz et al., 2004) , and to exert antiproliferative and proapoptotic effects on cancer cells (Orlando et al., 2012) .
Alternative designs for using probiotics are being explored and have been sometimes gathered under the term 'pharmabiotics'. Pharmabiotics encompass a broader set of substances, including live and dead microbes, microbial components, and microbe-produced substances (Shanahan and Collins, 2010; Patterson et al., 2014) . Moreover, some genetically modified probiotic strains have been designed to be used as vectors for targeted delivery of anti-inflammatory cytokines, vaccines, and antipathogenic molecules and have been also referred as 'immunobiotics' (Shigemori and Shimosato, 2017) .
Prebiotics are nondigestible foods that stimulate the growth and/or activity of bacteria in the GI tract. Some prebiotics, such as fructo-oligosaccharides and galactooligosaccharides, are anaerobically fermented into SCFAs (reviewed in Hardy et al., 2013) . Accordingly, some recent studies have provided further evidence that prebiotics can affect anxiety, learning, and memory, although data from human studies are still limited (Kao et al., 2016; Burokas et al., 2017) (Fig. 1) .
Here, we present and discuss the most remarkable data from animal studies and clinical trials that have analyzed the effects of probiotics on digestive disorders and emotional and pain-related illnesses.
Application of probiotics in the management of digestive disorders
The list of GI disorders that may be responsive to probiotics is huge (see Khoder et al., 2016 , and references provided therein). The use of probiotics as supplements or alternatives to oral antibiotic therapy in the treatment of GI infectious diseases [i.e. those produced by H. pylori, Salmonella, or C. difficile (Salas-Jara et al., 2016)] is very interesting, because they may restore the normal microflora, compete with the pathogenic resistant bacteria, and help patients to recover. Probiotics may avoid the use of antimicrobials or reduce the secondary effects associated with their use, such as antibiotic resistance or negative effects on the patients' health (Salas-Jara et al., 2016) . In a recent study, it was shown that probiotics may reduce infection complications in critically ill patients and may contribute to earlier recovery of gut function, although mortality was not proved to be reduced (Koekkoek and van Zanten, 2017) . Curiously, the Gram-negative probiotic Escherichia coli Nissle, 1917 was even more effective than Gram-positive probiotics (Lactobacilli spp.) at enhancing protective immunity against rotavirus in the gnotobiotic piglet model (Kandasamy et al., 2017) .
Focusing now on chronic digestive disorders, these may be divided into two main categories: organic and functional.
Organic disorders are those in which alterations of the gut wall structure are patent and clearly related to the disorder. In this category, all kinds of inflammatory-based alterations may be included: gastritis, gastric ulcer, gastric or colorectal cancer, and inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, microscopic colitis, celiac disease, etc. In contrast, the term 'functional', used for functional gastrointestinal diseases (FGID), including both functional dyspepsia and irritable bowel syndrome (IBS), indicates that structural or biochemical abnormalities that could explain the symptoms are not evident, based on routine clinical evaluations (Mearin et al., 2016; Tack and Drossman, 2017) .
Although in organic diseases pain may be present, probably because of the inflammatory condition itself, in FGID, pain is present but its etiology is not so clear: it may be related to alterations in motility and/or to microinflammation or low-grade inflammation [e.g. mastocytosis, which can be treated with antihistamine drugs (Fabisiak et al., 2017) ] and only recently is being considered (e.g. Holtmann et al., 2016 for a recent review of the pathophysiology of IBS).
In this review, we first provide some recent examples of studies of the potential of probiotics to treat three main organic disorders: gastric ulcer (and infection by H. pylori), IBD, and GI cancer. Thereafter, we illustrate the use of probiotics to treat FGID, and particularly, pain associated with IBS.
Inflammatory conditions in the gastrointestinal tract
Evidence from animal models and several animal models have been developed to test their efficacy in vivo. For example, Lactobacillus fermentum Suo inhibited, in a dose-dependent manner, HCl/ethanolinduced gastric injury in mice: the mechanisms involved improvements in the mucosal barrier; antioxidant activities; reduction of serum cytokines (IL-6, IL-12, TNF-α, and IFN-γ); increase in serum motilin, substantia P (SP), endothelin, somatostatin, and vasoactive intestinal peptide; and the normalization of several gastric proteins gene expression (Suo et al., 2016) . Moreover, in mouse models of gastric ulcers induced by alcohol, restraint cold stress, and pyloric ligation, Clostridium butyricum exerted antioxidative and anti-inflammatory effects leading to significantly reduced gastric mucosal injury (Wang et al., 2015a) .
In the IBD field, one recent study has shown that an iron-responsive Streptococcus thermophilus strain was able to ameliorate colitis induced by dextran sodium sulphate in mice. This has been suggested as an alternative to conventional probiotics, which in the iron-rich environment of the colon of patients with IBD (owing to bleeding and oral iron supplements) would not be as effective. The mechanism involved maintenance of mucosal barrier function and reduced bacterial translocation, thereby reducing immune stimulation and associated inflammation, leading to mucosal healing, as well as to reduced GI tract bleeding and weight loss (Bailey et al., 2017) . Interestingly, using the same model, the beneficial actions of E. coli Nissle, 1917 were potentiated when it was combined with iron supplementation in the form of ferrous sulphate (which is currently used in the clinic to supplement patients with IBD), but not with other iron supplements (Constante et al., 2017) . Moreover, in another recent report, Lactobacillus casei (01) was used alone and/or combined with oligofructose-enriched inulin in a trinitrobenzene sulfonic acid-induced rat model of colitis. This combination of the probiotic and the prebiotic (oligofructose-enriched inulin) was also tested after its encapsulation in chitosan-Ca-alginate microparticles, which showed the best anti-inflammatory effects (Ivanovska et al., 2017) . Thus, although in-vitro studies show that probiotics on their own may exert beneficial effects in inflammatory conditions, a currently hot topic of research in preclinical studies is to optimize their invivo effects, mainly through the combination (after encapsulation or not) with other compounds (prebiotics, nutrients, nutraceuticals, etc.) .
Regarding GI tract neoplasias, several recent in-vitro studies have shown that probiotics may exert antiproliferative and proapoptotic effects on cancer cells, although the mechanisms involved have not been completely elucidated (Orlando et al., 2012; Haghshenas et al., 2014) . In in-vitro studies using gastric cancer cell lines, Lactobacillus reuteri downregulated urokinase plasminogen activator/urokinase plasminogen activator receptor gene expression (Rasouli et al., 2017) . Moreover, in gastric cancer cell lines and xenograft models, ferrichrome (a siderophore) from L. casei ATCC334 induced apoptosis (Ijiri et al., 2017) . Lactobacillus salivarius Ren in rats and C. butyricum and Bacillus subtilis in mice could inhibit dysbiosis and suppress colon carcinogenesis (Chen et al., 2015; Zhang et al., 2015) .
Evidence from clinical studies
In clinical studies, probiotics may have a significant protective effect in several inflammatory conditions of the gut, although evidence is not available for all conditions. For example, it has recently been shown that probiotics may decrease the incidence of acidsuppressing drug-associated infections, especially in the elderly (Fisher and Fisher, 2017) . In both children and adults, a recent meta-analysis showed that the addition of probiotics improved H. pylori eradication rates, associated with immune system modulation, and very interestingly, probiotics improved medication tolerance and patient compliance with lower levels of nausea, vomiting, diarrhea, and epigastric pain (Lau et al., 2016) . In a recent review of the treatment of gastric ulcer, it was concluded that some probiotics may increase the efficacy and tolerability of the triple therapy, although data related to quadruple concomitant therapy are not definite yet (Gisbert, 2016) . Furthermore, it is not yet clear what are the specific probiotic(s), antibiotic(s), and patient factors that might predict benefit from probiotic supplementation in the treatment of gastric ulcer and H. pylori infection (Boltin, 2016) .
Similarly, in the IBD field, a very recent meta-analysis, considering a total of 22 randomized clinical trials, showed that VSL#3, a mixture of eight probiotic bacterial strains, may be effective in inducing remission in active ulcerative colitis, and that probiotics may be as effective as 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis. However, the efficacy of probiotics in Crohn's disease remains uncertain, and more evidence from randomized control trials is required (Derwa et al., 2017) . Similar results were obtained by another research group (Ganji-Arjenaki and Rafieian-Kopaei, 2017).
In GI cancer, probiotics may also play a role in the clinic. In a study using a Chinese cohort, small intestinal bacterial overgrowth was related to GI cancer (gastric and colorectal), and patients were treated with a Bifidobacterium triple viable capsule, which improved overgrowth of small intestinal bacterial and alleviated concomitant GI cancerrelated symptoms (Liang et al., 2016) . In addition, probiotics can prevent the toxic effects (diarrhea) of chemotherapy and radiotherapy in patients with cancer (Osterlund et al., 2007; Chitapanarux et al., 2010) , suggesting, once again, that restoration of normal microbiota plays a crucial role in these effects.
Functional gastrointestinal disorders and visceral pain
Evidence from animal models
In a very recent study, using GF mice, gut microbiota emerged as a requirement for normal visceral pain sensation (Luczynski et al., 2017) . Actually, GF mice (without microbiota) displayed visceral hypersensitivity, accompanied by increases in TLR and cytokine gene expression in the spinal cord, as well as changes in brain areas involved in pain processing, such as the anterior cingulate cortex and periaqueductal gray (Luczynski et al., 2017) . In contrast, probiotic administration has been reported to decrease visceral pain and improve GI tract motility. The administration of Lactobacillus spp. (Lactobacillus rhamnosus and L. reuteri) increased enteric neuron excitability, modulated intestinal motility Wang et al., 2010a Wang et al., , 2010b , and up-regulated mu-opioid and cannabinoid receptors expression, in rats and mice, leading to visceral analgesia (Rousseaux et al., 2007) . In addition, excitability of the dorsal root ganglia in response to colorectal distension is prevented by L. rhamnosus treatment , and L. farciminis exerts antinociceptive effects by altering central sensitization (Ait-Belgnaoui et al., 2009). A recent study by Darbaky et al. (2017) showed that treatment with two probiotics derived from the probiotic bacterial strain L. rhamnosus may attenuate peripherally and centrally induced visceral hypersensitivity in rats, and it was suggested that this treatment may be effective in the treatment of IBS symptoms.
Chronic visceral hypersensitivity occurring in adulthood in rats that received neonatally an intracolonic instillation of zymosan was attenuated by L. rhamnosus ATCC 53103 (Lactobacillus GG; LGG) and, to a lesser extent, by a prebiotic mix (galactooligosaccharides and polydextrose) (Kannampalli et al., 2014) . Furthermore, LGG was found to alter the levels of brain neurotransmitters, such as serotonin, noradrenaline, and dopamine, all of which are involved in pain modulation (Marks et al., 2009) . Treatment with live and killed L. reuteri prevented the pain response to colorectal distension, by decreasing distension-induced electrophysiological neuronal activity in the dorsal root ganglion (Kamiya et al., 2006) . A decrease of normal visceral perception and chronic colonic hypersensitivity, elicited by butyrate, was also observed after oral treatment with Lactobacillus acidophilus NCFM (Rousseaux et al., 2007) .
Short-term and long-term stress models are widely used such as IBS-like models, as stress induces gut hyperpermeability and visceral hypersensitivity in response to colorectal distension (Theodorou et al., 2014) . For example, chronic fatigue was induced in rats by forcing them to swim in water till exhaustion [prolonged forced swim test (FST)]. In this test, oral administration of L. acidophilus significantly decreased immobility and postswim fatigue time and attenuated oxidonitrosative stress and TNF-α levels (Singh et al., 2012) . The early neonatal period has been described as critical for the microbial colonization of the GI tract. In this regard, maternal separation, an established model of early life stress, has been reported to alter microbiome composition in monkeys and rats, a change that was associated with exaggerated visceral pain responses, in the rat, that persist in adulthood (Barouei et al., 2012) . In the IBS rat model of neonatal maternal separation, early life administration of VSL#3 reduced visceral pain perception and reset colonic expression of subsets of genes mediating pain and inflammation (Distrutti et al., 2013) , suggesting that changing the neurochemical milieu during the painful experience can modify the changes in visceral pain responses induced during infancy.
Strain specificity might be a key factor to consider when using probiotics to treat/avoid visceral pain. Thus, the efficacy of three different probiotics (L. salivarius UCC118, Bifidobacterium infantis 35624, and Bifidobacterium breve UCC2003) on the abdominal response to colorectal distension was compared using viscerally normosensitive rats (Sprague-Dawley) and viscerally hypersensitive rats (Wistar Kyoto); only B. infantis 35624 was able to reduce the colorectal distension-induced pain behavior in both rat strains (McKernan et al., 2010) . Additionally, in two stress models in rats (acute restraint stress and neonatal maternal deprivation), three probiotic strains were evaluated: Bifidobacterium lactis (NCC362), Lactobacillus johnsonii (NCC533), and L. paracasei (NCC2461) (Lpa). Only treatment with Lpa significantly improved stress-induced visceral pain and restored normal gut permeability, further highlighting that particular live bacteria strains and their metabolites generated in the medium may be required to improve stress-induced IBS-like symptoms (Eutamene et al., 2007) . Remarkably, a more recent study has highlighted the contribution of gut microbiota to both intestinal and behavioral manifestations of IBS (De Palma et al., 2017) . In this study, GF mice showed faster GI transit, intestinal barrier dysfunction, innate immune activation, and anxiety-like behavior when colonized with fecal microbiota from patients with IBS with diarrhea, but not if colonized with healthy control fecal microbiota (De Palma et al., 2017) .
Evidence from clinical studies
There are some systematic reviews and meta-analyses that have explored the probiotic effects on abdominal or visceral pain in patients with IBS. In general, the results show a significant reduction of pain in both adult and child populations after probiotic treatment (Didari et al., 2015) . However, a more recent meta-analysis showed that B. infantis (35624) did not affect abdominal pain, whereas a mixture of probiotics containing B. infantis significantly reduced abdominal pain in adult patients with IBS (Yuan et al., 2017) , highlighting that B. infantis (35624) combined with other probiotic strains could result in a more effective strategy to manage pain in patients with IBS. Similarly, Saccharomyces cerevisiae (CNCM I-3856) was also able to significantly improve IBS symptoms, with a 12.3% reduction of abdominal pain (Cayzeele-Decherf et al., 2017).
In the same direction, L. rhamnosus (GG and VSL#3) was associated with a significantly higher number of responders to treatment in a pediatric population experiencing abdominal pain-related FGID (Rutten et al., 2015) . Moreover, a recent review has found low-to-moderate quality evidence that probiotics ameliorate pain in children with recurrent abdominal pain (Newlove-Delgado et al., 2017).
Taken together, probiotics seem to be an effective strategy to manage pain associated with IBS, although the selection of which species and strains are most beneficial still remains unclear (Ford et al., 2014) .
Evaluation of probiotics in pain disorders
A relatively limited number of studies has investigated the influence of gut microbiota on pain and nociceptive processes (Rea et al., 2017) . Indeed, most of the research has focused on IBS, one of the FGID, where there is more evidence for the effectiveness of probiotics administration (Didari et al., 2015; Tiequn et al., 2015) . As previously mentioned, evidence for the use of prebiotics in IBS comes from animal studies and is mainly based on their ability (i) to modulate visceral sensitivity and (ii) to enhance intestinal barrier function and immunity (Theodorou et al., 2014) .
Although preclinical studies have focused on IBS models, clinical studies have also addressed the role of probiotics in chronic fatigue syndrome and other conditions. Indeed, there is some evidence for the effectiveness of probiotics in chronic fatigue syndrome. In an exploratory study, Sullivan et al. (2009) evaluated the effect of L. paracasei spp. Paracasei F19, L. acidophilus NCFB 1748, and B. lactis Bb12 on fatigue and physical activity in 15 patients diagnosed with chronic fatigue syndrome. Participants improved their neurocognitive functions, although no significant changes were reported in either fatigue or other variables measured, related to health and physical activity (Sullivan et al., 2009) . Rao et al. (2009) found that patients with chronic fatigue syndrome, treated for 2 months with L. casei strain Shirota (LcS), showed a significant improvement in anxiety as compared with placebo. Groeger et al. (2013) assessed the effect of oral administration of B. infantis (35624), for 6-8 weeks in patients with chronic fatigue syndrome; inflammatory biomarkers and plasma cytokine levels were evaluated, and the results showed that the probiotic treatment reduced plasma levels of C-reactive protein, IL-6, and TNF-α.
Probiotics have also revealed their efficacy in the management of rheumatoid arthritis. The combination of the probiotic, Bacillus coagulans (GBI-30, 6086) with standard antiarthritic medication, for 60 days, notably enhanced analgesia, as evidenced by an improvement in the pain scale as well as in the patient pain assessment score. In addition, a greater improvement in patient global assessment and self-assessed disability was also assessed after the probiotic administration (Mandel et al., 2010 ). An additional study showed that the administration of L. casei (01) to patients diagnosed with rheumatoid arthritis for 8 weeks induced a decrease in the disease activity score and significantly improved the inflammatory status of these patients. Probiotics seemed to decrease the proinflammatory cytokines TNF-α, IL-6, and IL-12, although no changes were observed in IL-1β levels (Vaghef-Mehrabany et al., 2014) . Therefore, probiotics may emerge as a potential adjunctive therapy for patients with rheumatoid arthritis.
Despite a theoretical rationale for probiotic therapy in other pathologies such as spondyloarthritis, no benefits have been demonstrated in clinical trials. The combination of probiotics, Streptococcus salivarius (K12), B. lactis (LAFTI B94), and L. acidophilus (LAFTI L10), for 12 weeks, did not achieve any difference over placebo in any of the core domains analysed: Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Functional Index, and Maastricht Ankylosing Spondylitis Enthesitis Score. Thus, in this randomized controlled trial, the probiotic combination administered did not demonstrate significant benefit over placebo (Jenks et al., 2010) .
Application of probiotics in emotional disorders
As already described, the microbiota plays an essential role in GI diseases (Martin and Kochhar, 2015) , and surprisingly, it seems also to be critically related to brain physiology and behavior, thus possibly affecting mental health (Cryan and Dinan, 2012; Borre et al., 2014; Dinan et al., 2014; Carabotti et al., 2015) . Actually, probiotics have emerged as a potential intervention to manage anxiety and depression, at least in animal models. Indeed, the term psychobiotics was coined to describe the beneficial effects of probiotics in patients experiencing psychiatric illnesses .
Evidence from preclinical models
Preclinical studies have focused on anxiety and depression . The administration of probiotics consistently induces anxiolytic-like and antidepressivelike responses in rodents. The long-term administration of L. rhamnosus (JB-1) enhanced the exploration of the open-arms of an elevated plus maze, indicative of an anxiolytic-like effect, although the animals did not change their behavior in the stress-induced hyperthermia test. Moreover, the stress-induced corticosterone response was significantly attenuated by the administration of this probiotic (Bravo et al., 2011) . Similar results have been reported in rats, tested in the elevated plus maze, following the administration of Lactobacillus fermentum (strain NS9) (Wang et al., 2015b) ; in mice, evaluated in the Barnes test, after Lactobacillus helveticus (ROO52) administration (Ohland et al., 2013) ; and in GF mice administered Lactobacillus plantarum (PS128) and evaluated in the elevated plus maze (Liu et al., 2016) .
More importantly, probiotics also act as effective anxiolytics in animal models with an anxious phenotype. Animals exposed to a protocol of early life stress, maternal separation (3 h/day from days 4 to 19), present an altered activity of the hypothalamus-pituitary-adrenal (HPA) axis, demonstrating increased basal serum corticosterone levels; the administration of a mixture of two strains of Lactobacillus spp. was able to revert the enhanced level of circulating corticosterone (Gareau et al., 2007) . In mice, L. helveticus (ROO52) successfully prevented the negative effects of a western-style diet on anxiety (Ohland et al., 2013) . Immunodeficient B cell and T-cell-deficient Rag1 (− / − ) mice exhibit increased anxiety levels, in the lightdark box, as well as augmented levels of circulating corticosterone; the administration of a mixture of Lactobacillus was able to prevent the former, while not affecting the HPA axis activity (Smith et al., 2014) . However, some negative data have also been reported, for example, the administration of L. rhamnosus (NCC4007) was not effective in the management of the anxious state reported in an animal model of low-grade colitis (Bercik et al., 2010) , although, in this case, the administration of another probiotic, Bifidobacterium longum (NCC3001), successfully reverted the anxiety-like behavior associated with chronic colitis (Bercik et al., 2010 (Bercik et al., , 2011 . The combination of L. helveticus (R0052) and B. longum (R0175) has also been investigated, and promising anxiolytic-like effects were reported in rats using the conditioned defensive burying test of anxiety (Messaoudi et al., 2011) . More recently, the administration of L. rhamnosus (JB-1) was able to prevent the stress-induced anxiety-like behavior observed in mice chronically exposed to social defeat. In the study, L. rhamnosus (JB-1) successfully prevented the deficits in social interaction with conspecifics, although this probiotic was not able to counteract the avoidance of the aggressor, thus indicating a possible dissociation between several forms of anxiety-like behavior (Bharwani et al., 2017) .
The vagus nerve seems to play a pivotal role in the anxiety-like effects of probiotics. For example, the anxiolytic-like effects of L. rhamnosus (JB-1) were not found in vagotomized mice (Bravo et al., 2011) . Moreover, in the chronic colitis animal model, anxietylike behavior is vagally mediated, and the anxiolytic effect of B. longum required vagal integrity (Bercik et al., 2011) . Bacteria may alter the excitability of enteric neurons, which may signal to the central nervous system by activating vagal pathways at the level of the ENS. Some other neuroactive substances released by gut bacteria, such as serotonin, noradrenaline, and dopamine, may also be involved in the emotional effects of probiotics. Potential mechanisms underlying the emotional actions of probiotics are discussed in the next section.
Regarding antidepressant-like effects, controversial data have been reported. The long-term administration of L. rhamnosus (JB-1) significantly reduced the time animals spent immobile in the FST (Bravo et al., 2011) , whereas L. plantarum (PS128) did not affect depressionlike behavior in the FST in GF mice (Liu et al., 2016) . However, the results become consistent if probiotics are tested in 'depressed' animals. B. infantis (35624) effectively reversed the depressive phenotype of animals submitted to the maternal separation protocol (Desbonnet et al., 2010) , and L. helveticus (NS8) demonstrated antidepressant properties in the chronic restraint stress model of depression (Liang et al., 2015) . In these two studies, probiotics had effects similar to those of the usually prescribed antidepressant citalopram (Desbonnet et al., 2010; Liang et al., 2015) . In addition, the combination of probiotics (L. helveticus and B. longum) was effective in the prevention of depressive-like symptoms associated with an animal model of myocardial infarction; in particular, this combination reversed the immobility in the FST, the abnormal levels of social interaction, and the impaired processing of emotional memory, which were observed following the surgical intervention (Arseneault-Bréard et al., 2012).
Probiotics have shown a positive effect on cognitive function. Recent studies have reported that mice fed with L. rhamnosus (JB-1) displayed an enhanced memory towards cues and context (Bravo et al., 2011) ; and mice fed with B. longum (1714) performed better in the object recognition test (discriminating faster between the two objects than other groups), in the Barnes maze (performing fewer errors than other groups) as well as in the fear conditioning test (Savignac et al., 2015) . Notably, probiotics seem not only to improve cognition per se but also to counteract the memory impairments reported in several animal models. As an example, Lactobacillus fermentum (strain NS9) alleviated an ampicillin-induced impairment in memory retention in the Morris water maze (Wang et al., 2015b) , and L. helveticus (ROO52) prevented the memory impairment associated with a western-style diet (Ohland et al., 2013) (Table 1) .
Recent studies have also proposed probiotics, in particular L. rhamnosus (GG), as a valid strategy for the treatment of obsessive-compulsive disorder as it effectively normalized the hyperlocomotion, stereotypes, and perseverative behavior observed in an animal model of this disorder (Kantak et al., 2014) . Probiotics have opened new avenues in the management of emotional disorders; however, little is known yet regarding the underlying mechanisms.
Evidence from human studies
The reported anxiolytic and antidepressant properties of probiotics may be effectively translated into the human population, although further studies and clinical trials are still needed.
One of the first studies, by Benton et al. (2007) , was a double-blind placebo-controlled trial in which a yogurt containing L. casei Shirota, or a placebo, was administered for 3 weeks. Notwithstanding that the probiotic did not generally change the mood, a trend toward improvement of mood in those who were more depressed was reported. In line with this observation, LcS administered daily for 2 months to a population experiencing chronic fatigue syndrome decreased in anxiety symptoms, evaluated by using the Beck Depression and Anxiety Inventories (Rao et al., 2009) . The combination of L. helveticus (R0052) and B. longum (R0175) also seems to be useful as an antistress/ antianxiety agent in healthy volunteers (Messaoudi et al., 2011) . Similarly, a recent study reported that the B. longum 1714 strain alone can ameliorate both the physiological and psychological response to an acute stressor (cold pressor test) in healthy human adults and also reduced daily reported stress. In addition, this probiotic induced a subtle improvement in visuospatial memory performance, as well as enhanced frontal midline electroencephalographic mobility consistent with the cognitive enhancement observed (Allen et al., 2016) . However, in a more recent study, L. rhamnosus (JB-1) was not superior to placebo in modifying stress-related measures in healthy male participants evaluated during and after a socially evaluated cold pressor test (Kelly et al., 2017) .
In parallel with the findings in preclinical studies, the administration of probiotics is a more powerful tool in humans when treating altered emotional states. Probiotics effectively ameliorated anxiety symptoms in patients with laryngeal cancer before surgery (Yang et al., 2016) . Administration of the probiotics LcS exerted beneficial effects, preventing the onset of physical, physiological, and psychological symptoms reported by healthy subjects exposed to a stressful situation, in particular, a national official exam for promotion, (Kato-Kataoka et al., 2016) . The authors proposed that both the HPA axis and the serotonin system could be affected by probiotics, and this may account, at least partially, for their anxiolytic-like actions (Kato-Kataoka et al., 2016) .
Food supplementation with a multispecies probiotic has been proposed as a strategy to reduce negative thoughts associated with sad mood; therefore, it represents a potential preventive strategy for depression (Steenbergen et al., 2015) . Indeed, an altered microbiota composition has been reported in patients diagnosed with major depressive disorder (Jiang et al., 2015) . More recently, the antidepressant properties of probiotics have been confirmed in a depressed population: probiotic administration effectively decreased the depressive score of patients diagnosed with major depressive disorder (Akkasheh et al., 2016) . Probiotics, in a yogurt or in a multispecies probiotic capsule, were also reported to elicit significant improvements in both a general health questionnaire and the Depression Anxiety and Stress Scale in petrochemical workers (Mohammadi et al., 2016) . More recently, L. rhamnosus HN001 (HN001) was tested in gestating women and was shown to reduce maternal depression and anxiety in the postpartum period (Slykerman et al., 2017) (Table 2 ). The brain response to probiotics has also been investigated by functional MRI (fMRI). A small population of healthy women was exposed to a probiotic, containing Bifidobacterium animalis subsp Lactis, Streptococcus thermophiles, L. bulgaricus, and Lactococcus lactis subsp Lactis, and then tested in the fMRI using an emotional faces attention task and resting brain activity. The study revealed that this probiotic affected the activity of brain regions that control central processing of emotion and sensation (Tillisch et al., 2013) . A prospective study evaluated the effects of B. longum NCC3001 (BL) on anxiety and depression in patients with IBS. BL reduced depression scores but not anxiety scores and increased quality of life: in addition, fMRI data showed that BL reduced responses to negative emotional stimuli in multiple brain areas such as amygdala and frontolimbic regions (Pinto-Sanchez et al., 2017) . In a more recent study in healthy women, Tillisch et al. (2017) identified two bacterial genus-based clusters: one with greater abundance of Bacteroides and another with a predominance of Prevotella. The Prevotella group showed less hippocampal activity while viewing negative valences images and was associated with differences in emotional, attentional, and sensory processing regions. For gray matter, the Bacteroides cluster showed greater prominence in the cerebellum, frontal regions, and the hippocampus (Tillisch et al., 2017) . These results further support the concept of brain-gut-microbiota interactions in healthy humans. However, further research is still needed to better understand the specific interaction between gut microbes, brain, and affect in humans.
Putative mechanisms underlying the central effects of probiotics
Probiotics, as previously reviewed, play a relevant role in the management of GI, emotional and pain-related disorders. Many mechanisms have been shown to be involved in this bidirectional pathway between the The elevation observed before the examination in the placebo group was not evidenced Faecal serotonin
Increased 2 weeks after the examination Subjects were exposed to stress, i.e., in particular, a national official exam for promotion Slykerman et al. (2017) Women recruited at 14-16 weeks gestation (380) microbiota and the brain. Communication through neural pathways is mainly mediated through the vagus nerve and the ENS. The HPA axis -through glucocorticoidsas well as the immunological pathway -through the modulation of cytokines -also seem to be essential in this communication. More recently, microbiota has been proposed as an epigenetic entity (Stilling et al., 2014) . However, the mechanisms involved in the effects of microbiota are still under discussion (see Carabotti et al., 2015; Cryan and Dinan, 2012; El Aidy et al., 2016; Wall et al., 2014 , for an updated review of the topic).
Probiotics may alter emotionality and pain perception by acting on the central nervous system. Increased neuron excitability has been reported at several levels of the brain-gut axis, that is, ENS, spinal cord, and supra spinal sites (Feng et al., 2012) . At the supra-spinal sites, interactions with emotional or stressful influences can modulate visceral sensitivity resulting in increased pain perception (Hertig et al., 2007) .
The vagus nerve has emerged as a crucial factor in the emotional effects of probiotics. As previously reported, the anxiolytic-like effects of L. rhamnosus (JB-1) were not found in vagotomized mice (Bravo et al., 2011) , and B. longum required vagal integrity to exert its anxiolytic effects in an animal model of colitis-induced anxiety (Bercik et al., 2011) . B. longum metabolites decreased excitability of enteric neurons (Bercik et al., 2011) , which may in turn signal to the central nervous system by activating vagal pathways at the level of the ENS. The anxiolytic actions of probiotics may be vagally mediated; however, the involvement of the vagal nerve in the analgesic effects of probiotics has not yet been investigated.
Gut microbiota produces several microbial metabolites, such as SCFAs, vitamins, and chemotactic peptides De Palma et al., 2014; Sherwin et al., 2016) that can bind to receptors expressed on enteroendocrine cells to facilitate secretion of a variety of peptides that can act locally on nearby intestinal epithelium and immune cells, activate neurons of the ENS, and also act in remote sites such as the brain (Furness et al., 2013) .
Increasing data give support to microbially produced molecules with neuroactive functions, such as γ-aminobutyric acid (GABA), serotonin, catecholamines, and acetylcholine, which can modulate neural signalling within the ENS, when released in the intestinal lumen, and consequently interact with brain function and behavior (Patterson et al., 2014) . Actually, many of these neurotransmitters have been isolated from bacteria within the human gut (Wall et al., 2014) . Chronic live PS128 ingestion significantly increased the levels of both serotonin and dopamine in the striatum but not in the prefrontal cortex or hippocampus. The administration of B. infantis was able to restore basal NA concentrations in the brainstem of animals exposed to early maternal separation (Desbonnet et al., 2010) . L. helveticus (NS8) restored hippocampal serotonin and norepinephrine levels in an animal model of depression, the chronic restraint stress model, in rats (Liang et al., 2015) . In humans, some species of Lactobacillus have been reported to prevent the increase in plasma L-tryptophan, a precursor of serotonin, detected before the exposure to a certain stress, and was able to increase the concentration of fecal serotonin in the long term (Kato-Kataoka et al., 2016) . Region-dependent alterations in GABA A and GABA B receptor expression have been described following long-term treatment with L. rhamnosus (JB-1): the probiotic increased GABA B in cortical regions (cingulate and prelimbic) with concomitant reductions in the hippocampus, amygdala, and locus coeruleus, whereas GABA A was reduced in the prefrontal cortex and amygdala but increased in the hippocampus (Bravo et al., 2011) .
Neurotrophins, and more specifically brain-derived neurotrophic factor (BDNF), play a central role in the pathophysiology of depression. The administration of B. longum restored the diminished hippocampal BDNF levels observed in an animal model of low-grade colitis (Bercik et al., 2010) . Moreover, the administration of L. helveticus (NS8) increased hippocampal BDNF mRNA expression, thus suggesting a common mechanism of action between probiotics and actual antidepressants (Liang et al., 2015) . However, discrepant results, in which no changes in BDNF levels were observed, have also been reported for B. longum (Bercik et al., 2011) .
The HPA axis might also be involved in the microbiotabrain interaction. Despite inconsistencies, probiotics have been reported to affect HPA activation. L. helveticus (NS8) decreased plasma corticosterone (CORT) and adrenocorticotropic hormone levels (Liang et al., 2015) , and B. infantis restored the changes in amygdala corticotrophin-releasing factor mRNA levels following maternal separation (Desbonnet et al., 2010) . These changes in HPA activation might play a critical role in the emotional actions of probiotics, although the connection pathway between microbiota and the HPA axis deserves further investigation.
Probiotics may also alter emotionality and pain perception by acting through microbiota-immune interactions. Cytokines produced in the GI tract might be able to cross the blood-brain barrier, affecting the central nervous system, with a potential effect on mood and behavior. L. helveticus (NS8) increased plasma IL-10 levels (Liang et al., 2015) , whereas B. infantis normalized the enhanced peripheral IL-6 release reported in the maternal separation animal model (Desbonnet et al., 2010) .
Pain relief actions of probiotics have been related to the opioid and cannabinoid systems. Treatment with Lactobacillus spp. in an animal model of IBD up-regulated colonic mu-opioid receptor and cannabinoid receptor 2 expression in rats, together with a reduction in visceral sensitivity (Rousseaux et al., 2007) . In humans with mild to moderate abdominal pain, the probiotic Lactobacillus acidophilus (NCFM) increased colonic mu-opioid receptor expression, as well as downstream signalling as measured by enterocyte STAT3-phosphorylation. In contrast, cannabinoid receptor 2 expression was decreased (Ringel-Kulka et al., 2014) . Although the opioid system emerges as a plausible mechanism of action by which probiotics modulate pain sensation in humans, research on the role of the endocannabinoid system deserves further investigation. In a recent study, feeding rats with L. reuteri (DSM 17938) inhibited perception of painful gastric distension, and the vanilloid receptor TRPV1 has emerged as a specific target channel for a probiotic with potential therapeutic properties (Perez-Burgos et al., 2015) (Fig. 2 ).
Conclusions and future perspectives
There is no doubt that probiotics are not only a promising tool for the treatment of certain diseases but also a valuable prevention strategy. A recent study identified a symbiotic treatment, a combination of L. plantarum ATCC-202195 plus fructooligosaccharide, was an effective strategy to potentially prevent neonatal sepsis in developing countries (Panigrahi et al., 2017) . The evidence gathered and presented in the present review highlights probiotics as a safe and effective strategy in the management of several GI, emotional, and pain disorders. In general, human studies can only infer correlations and not causality in the relationship between gut microbiota and behavior, so most evidence for the potential of probiotics comes from animal models, as presently described. Notwithstanding, the translation from animal studies to the clinic presents important challenges and deserves further investigation. The design and performance of larger trials is urgently needed to verify whether these new strategies might be useful not only for the treatment of disorders affecting the GI tract but, importantly, also for emotional and pain disorders not directly related to the GI tract. In this regard, we have recently described a protocol for the evaluation of the efficacy of probiotics in fibromyalgia (Roman et al., 2017) .
Dietary supplementations with probiotics and prebiotics are the most widely used dietary adjuncts to modulate the gut microbiota. However, the effectiveness of a specific single probiotic strain over a probiotic cocktail combination should be demonstrated. Moreover, selection from a reputable supplier, with appropriate documentation of contents and shelf life, anticipation of strain-specific effects, and avoidance of cocktails without documentation of the activities of each ingredient with absence of interstrain antagonism, are some factors that should be considered when selecting the proper probiotic treatment (Shanahan and Collins, 2010) . To optimize the Putative mechanisms underlying the central effects of probiotics. HPA, hypothalamus-pituitary-adrenal.
Potential clinical application for probiotics Roman et al. 115 effects of probiotics, specific combinations of bacteria might be of special interest, although the combination with other nutrients and/or nutraceuticals, or even the design of the vehicles, may play a critical role in their effects (Nguyen et al., 2016) .
Evidence of efficacy is starting to emerge from clinical trials, as reported in the previous sections, although one of the challenges in translating the findings from probiotics effectiveness is the need to provide evidence not only in healthy subjects but also in animal models and patients experiencing specific illnesses. Moreover, a cultural change by the food and probiotic industry is required to carry out the level of investment required for probiotics clinical trials to prove efficacy .
Remarkably, sex has also emerged as a critical factor in gut-microbiota-brain interactions. In this regard, a recent study has shown an association between yogurt consumption and gut microbiota in a healthy cohort; it reported that not only was adult human gut microbiota different in relation to host sex, but the yogurt-microbiota correlation also seemed to differ in a sex-specific manner (Suzuki et al., 2017) . Therefore, sex is a factor that should not be left unattended either in animal studies or in clinical trials.
Last but not least, a better understanding of the mechanisms involved may open new avenues for the design of therapeutics that could enhance the clinical benefits pursued.
